Sotera Health Company research snapshot
SHC AI stock analysis currently reads Sotera Health Company as an essential provider of outsourced sterilization, cobalt-60 supply, and lab testing for medical devices and pharmaceuticals, with improving financial momentum and a known legal overhang. This page uses scenario ranges, not certain price predictions. As of the August 3, 2026 data cutoff, the reference quote was $17.86 from the July 31, 2026 close, market capitalization was about $5.09 billion, and the main decision point was whether earnings growth keeps validating the forward valuation while the ethylene oxide (EtO) regulatory and litigation overhang continues to fade. This is informational research and not investment advice.
Current price
$17.86
Market cap
$5.09 billion
AI score
60 / 100
Rating
Essential service franchise with improving margins and a legal overhang
Trend status
Medium-term uptrend with price above the 50-day and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Sotera Health sells mission-critical outsourced sterilization, cobalt-60 supply, and lab testing that medical device and pharmaceutical customers require before products reach patients. Demand is non-discretionary and recurring. | Medium-high |
| Moat | Barriers come from customer revalidation and qualification costs, a dense global facility network, regulatory licensing, and the Nordion cobalt-60 supply position. The EtO legal overhang partly offsets these advantages. | Medium |
| Management | A planned leadership transition put Alton Shader in the CEO role on May 26, 2026, with Michael Petras remaining as Executive Chairman. Recent board additions and a secondary offering that lifted public float to about 90% support the governance profile. | Medium |
| Financial trend | Financials are improving. TTM revenue rose 7.4%, Q1 2026 revenue grew 10% with adjusted EBITDA up 10.5%, and free cash flow stayed positive. Debt remains high with net leverage at 3.2x. | Medium-high |
| Valuation | TTM P/E of 43.7x is high, but forward P/E of 18.2x and EV/EBITDA of 13.9x price in continued earnings normalization toward 2026 adjusted EPS guidance of $0.93 to $1.01. | Medium-low |
| Technical trend | Price sits above the 50-day moving average near $16.82 and the 200-day moving average near $16.48, with RSI near 57. The medium-term trend is up but the stock has been consolidating since mid-July. | Medium |
| Risk level | The thesis can fail if EtO regulation tightens, litigation costs climb beyond reserves, leverage becomes a constraint, or growth guidance is cut. Q2 2026 earnings on August 6 is a near-term catalyst. | Medium-high |
| AI confidence | Medium-high confidence on market data and reported financials. Lower confidence on forward returns because the EtO legal path is largely binary. | Medium-high data confidence |
| Investment certainty | Low-medium certainty because the page gives a research framework, not a personalized buy or sell instruction, and the regulatory path remains uncertain. | Low-medium |
SHC AI stock forecast
The SHC AI stock forecast uses scenario ranges around the $17.86 reference quote rather than a point target. The bullish case requires earnings growth to keep beating guidance and the legal overhang to keep fading; the base case assumes guidance holds with normal volatility; the bearish case assumes an adverse regulatory or litigation event or a guidance cut.
$20.00 to $24.00
More likely if Q2 2026 earnings on August 6 beat guidance with continued margin expansion, analyst targets near the consensus $20.44 are confirmed, and the stock breaks above the $18.50 to $19.85 resistance zone toward the top of the analyst range.
$16.50 to $20.00
More likely if 2026 revenue guidance of $1.233 to $1.251 billion holds, legal costs stay manageable, and the stock continues to trade above the rising 200-day moving average with normal earnings-driven volatility.
$12.50 to $16.00
More likely if these risk paths appear: an adverse EtO regulatory decision or material litigation loss, leverage pressure given interest coverage near 2.6x, a cut to 2026 guidance, or a decisive close below the $16.50 support zone.
SHC AI technical analysis
SHC AI technical analysis starts from the $17.86 reference quote and chart data through July 31, 2026. Moving averages, RSI, and momentum figures come from chart data as of the data cutoff and should be confirmed in a live charting tool before trading, because this static page does not fetch request-time market data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $17.86 | Reference quote from the July 31, 2026 close used for this page as of the August 3, 2026 data cutoff. |
| Near support | $17.00 to $17.40 | Built from the July lows around $17.15 to $17.27 and recent consolidation. Treat as a planning zone, not a guaranteed floor. |
| 50-day moving average | $16.82 | Calculated from chart data as of the data cutoff. A loss of this level would signal weaker short-term momentum. |
| 200-day moving average | $16.48 | Long-term trend reference from chart data as of the data cutoff. The price holding above it supports the medium-term uptrend. |
| Near resistance | $18.40 to $18.55 | Formed by the July 10 and July 16 highs. A close above this zone would point toward the 52-week high of $19.85. |
| 52-week high | $19.85 | The upper boundary of the 52-week range. A break above this level with volume would signal a new high and stronger momentum. |
| Momentum | RSI near 56.7, medium-term uptrend | Positive but not extreme. The stock is up about 49.9% over 52 weeks but has been range-bound since mid-July. |
| Volume | Average daily volume about 2.99 million shares | Volume can spike on earnings, legal headlines, or regulatory news. Elevated turnover appeared around July 23 and July 28. |
| Volatility | Elevated monitoring priority | Beta of 1.77 means the stock moves more than the broad market. Use position sizing that can tolerate wide daily movement. |
| Invalidation | Close below $16.50 | A decisive close below the 200-day moving average near $16.48 with elevated volume would weaken the medium-term setup. |
SHC AI trading strategy
The SHC AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, defined stop levels, and a fresh check of filings and the August 6 earnings release before execution.
Wait for SHC to hold above the $17.00 to $17.40 support zone and push through the $18.40 to $18.55 resistance with volume that confirms buyer demand, ideally alongside a constructive Q2 2026 report.
A close below the support zone or a failed breakout should invalidate the setup. Monitor earnings, litigation reserves, and EtO regulatory headlines closely.
If SHC pulls back toward the 50-day moving average near $16.82 without a thesis-breaking legal or regulatory event, compare the price with the next earnings release and balance sheet disclosures before acting.
Do not average down without a predefined maximum loss and a fresh review of the business and litigation risk.
Track the evidence that matters most for Sotera Health: sterilization volume trends, Nordion cobalt-60 revenue timing, Nelson Labs stabilization, 2026 guidance vs. the $1.233 to $1.251 billion revenue range, and legal reserve adequacy.
Reduce confidence when price moves are driven by litigation headlines without matching fundamental evidence. The high debt load and interest coverage near 2.6x require monitoring of refinancing risk.
Investment research summary
Customers pay Sotera Health to prove that medical devices and pharmaceuticals are sterile and safe before use. The three segments are Sterigenics (contract sterilization), Nordion (cobalt-60 supply), and Nelson Labs (microbiological testing and advisory services).
The moat combines customer revalidation and qualification costs, a global facility network, regulatory licensing, and Nordion position in the cobalt-60 supply chain. The EtO legal overhang has added cost and reputation risk that narrows the advantage.
The thesis fails if EtO regulation tightens further, litigation costs exceed reserves, a customer or regulatory challenge hits the Sterigenics model, cobalt-60 supply is disrupted, or high leverage forces restrictive outcomes during an adverse scenario.
Alton Shader took over as CEO on May 26, 2026 in a planned transition, with Michael Petras staying as Executive Chairman. Board additions include Rich Kyle and Kenneth Krause. A May 2026 secondary offering of 31.84 million shares lifted public float toward 90%.
Sterilization and lab testing for healthcare sit in a secular growth market tied to aging populations and rising procedure volumes. The main uncertainty is environmental scrutiny of ethylene oxide, which affects one key sterilization method in the United States.
At 43.7x TTM P/E but 18.2x forward P/E and 13.9x EV/EBITDA, the market prices in earnings normalization toward 2026 adjusted EPS guidance of $0.93 to $1.01. Safety margin is thin if growth disappoints or litigation costs escalate.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SHC price | $17.86 | Stock Analysis quote page (CBOE real-time) | August 3, 2026 |
| Market capitalization | $5.09 billion, consistent with $17.86 x 285.17 million shares outstanding | Stock Analysis statistics | August 3, 2026 |
| Enterprise value | $7.05 billion | Stock Analysis statistics | August 3, 2026 |
| Revenue (TTM) | $1.189 billion, up 7.4% | Stock Analysis financials | August 3, 2026 |
| Net income (TTM) | $117.79 million | Stock Analysis financials | August 3, 2026 |
| EPS (TTM) | $0.41 | Stock Analysis financials | August 3, 2026 |
| 2026 revenue guidance | $1.233 to $1.251 billion | Sotera Health Q1 2026 press release | August 3, 2026 |
| 2026 adjusted EBITDA guidance | $632 to $641 million | Sotera Health Q1 2026 press release | August 3, 2026 |
| Q1 2026 net revenues | $280.05 million, up 10.0% (6.5% constant currency) | Sotera Health Q1 2026 press release | August 3, 2026 |
| Free cash flow (TTM) | $96.84 million | Stock Analysis statistics | August 3, 2026 |
| Cash and equivalents | $314.37 million (March 31, 2026) | Stock Analysis statistics / company balance sheet | August 3, 2026 |
| Total debt and net leverage | $2.27 billion total debt; net leverage 3.2x | Stock Analysis statistics / Q1 2026 press release | August 3, 2026 |
| Debt to equity and interest coverage | Debt to equity 3.65; interest coverage 2.55 | Stock Analysis statistics | August 3, 2026 |
| Analyst consensus and target | Buy; average target $20.44 (range $16 to $24) | Stock Analysis forecast | August 3, 2026 |
| 52-week range and beta | $11.00 to $19.85; beta 1.77 | Stock Analysis statistics | August 3, 2026 |
| Exchange | NasdaqGS | Stock Analysis quote page | August 3, 2026 |
This SHC AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 3, 2026, may be incomplete, and can be wrong if new filings, market prices, company events, or macro conditions change. The EtO regulatory and litigation environment creates inherent uncertainty that cannot be modeled with precision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
